結節性痒疹治療の世界市場-2023年～2030年

市場概要

結節性痒疹治療の世界市場規模は2022年に9億6,430万米ドルに達し、2030年には11億米ドルに達することで有利な成長が予測されています。結節性痒疹治療の世界市場は、予測期間2023-2030年にCAGR 3.7%を示しています。

結節性痒疹は、かゆみを伴う結節を伴う慢性皮膚疾患です。結節性痒疹の治療は、かゆみ、炎症、結節の形成を抑えることを目的としているが、普遍的に認められた標準治療はないです。治療の選択肢は限られており、広く受け入れられている標準治療は存在しないです。結節性痒疹の治療には、ヘルスケアプロバイダー、研究者、製薬会社、患者支援団体の協力が不可欠です。

結節性痒疹治療市場は、結節性痒疹の有病率の増加、カプサイシンクリームの需要増加、治療オプションの進歩と革新、エモリエント剤の採用増加、標的療法と生物製剤への関心の高まり、技術の進歩などの要因によって牽引されます。

市場力学

カプサイシンクリームの需要増加

カプサイシンクリームの需要増加は、予測期間中の結節性痒疹治療市場における市場シェアを牽引する重要な要因です。カプサイシンクリームは、結節性痒疹の包括的な治療アプローチの一環として使用することができます。症状の緩和を強化し、症状の全体的な管理を改善するために、コルチコステロイドや抗ヒスタミン薬などの他の局所薬や全身薬と併用することができます。

例えば、多くの地域では、カプサイシンクリームは処方箋なしで市販されています。このように入手しやすいため、結節性痒疹の症状の自己管理を求める患者や、処方箋なしの治療を好む患者にとって便利な選択肢となっています。

高額な治療費

高い治療費は、結節性痒疹に対する効果的な治療法へのアクセスを制限する可能性があり、特に十分な保険が適用されない患者や経済的な余裕のない患者にとっては大きな負担となります。このため、利用可能な治療選択肢にアクセスし、それを購入できる患者集団が少なくなる可能性があります。治療法によっては長期間の使用を必要とするものもあり、長期にわたる使用は患者にとって負担となり、治療レジメンの非遵守や治療成績の最適化につながる可能性があります。

高額な治療費は、特に公的資金による医療や保険制度のある地域では、ヘルスケアシステムに負担をかける可能性があります。限られたヘルスケア予算は、高価な治療へのアクセスを制限し、結節性痒疹治療の利用可能性と適用範囲に影響を与える可能性があります。

COVID-19の影響分析

COVID-19パンデミックは世界のヘルスケアサービスの混乱を招いた。皮膚科受診を含む緊急性のない診療予約や選択的処置は、多くの地域で延期または中止されています。これは結節性痒疹の診断と管理に影響を及ぼし、患者の治療アクセスを遅らせる可能性があります。

パンデミックは、潜在的なウイルスへの曝露を懸念してヘルスケアを求める行動を減らすなど、患者の行動に変化をもたらしました。結節性痒疹の患者は、診察や経過観察の受診を先延ばしにしたり避けたりしたため、過小診断や過小治療につながった可能性があります。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争とそれに関連する課題は、結節性痒疹に関連する研究開発活動から資源と注意をそらす可能性があります。医学研究に対する資金や焦点はより差し迫った優先事項へとシフトし、結節性痒疹に対する新たな治療選択肢や臨床試験の進展に影響を及ぼす可能性があります。

紛争はより広範な社会経済的影響を及ぼし、個人やヘルスケアシステムの経済的安定性や資源に影響を及ぼす可能性があります。経済的不安定、生計手段の喪失、避難生活により、患者やヘルスケア提供者の財源が制限され、結節性痒疹の治療費の妥当性や利用可能性に影響を及ぼす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • カプサイシンクリーム需要の増加
    • 結節性痒疹の有病率の増加
  • 抑制要因
    • 高い治療費
    • 限られた治療オプション
  • 機会
    • 治療オプションの進歩と革新
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 製品別

• 副腎皮質ホルモン
• 抗ヒスタミン薬
• エモリエント剤
• カプサイシンクリーム
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Menlo Therapeutics Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Pfizer Inc.
• Sanofi S.A.
• Kiniksa Pharmaceuticals Ltd.
• Astellas Pharma Inc.
• Eli Lilly and Company
• GlaxoSmithKline
• Galderma S.A.
• Trevi Therapeutics Inc.
• Regeneron Pharmaceuticals Inc.

第12章 付録

Market Overview

The Global Prurigo Nodularis Treatment Market size reached US$ 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.1 billion by 2030. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2023-2030.

Prurigo Nodularis is a chronic skin condition with itchy nodules. Treatment of prurigo Nodularis aims to reduce itching, inflammation, and the formation of nodules, but there is no universally accepted standard of care. Treatment options are limited and there is no widely accepted standard of care. Collaboration between healthcare providers, researchers, pharmaceutical companies, and patient advocacy groups is essential for prurigo nodularis treatment.

The prurigo nodularis treatment market is driven by factors such as the increasing prevalence of prurigo nodularis, increasing demand for capsaicin cream, advancements and innovations in treatment options, increasing adoption of emollients, growing interest in targeted therapies and biologics, and technological advancements.

Market Dynamics

Increasing Demand for Capsaicin Cream

The increasing demand for capsaicin cream is a significant factor driving the market share in the Prurigo Nodularis Treatment Market during the forecast period. Capsaicin cream can be used as part of a comprehensive treatment approach for prurigo nodularis. It can be used alongside other topical or systemic medications, such as corticosteroids or antihistamines, to enhance symptom relief and improve overall management of the condition.

For instance, In many regions, capsaicin cream is available over the counter without a prescription. This accessibility makes it a convenient option for patients seeking self-management of prurigo nodularis symptoms or those who prefer non-prescription treatments.

High Cost of Treatment

High treatment costs can limit access to effective therapies for prurigo nodularis, particularly for individuals who may not have adequate insurance coverage or financial resources. This can lead to a smaller patient population being able to access and afford the available treatment options. Some treatments may require long-term use, which can become burdensome for patients over time, leading to non-adherence to treatment regimens or suboptimal treatment outcomes.

High treatment costs can strain healthcare systems, especially in regions with publicly funded healthcare or insurance systems. Limited healthcare budgets may restrict access to costly treatments, affecting the availability and coverage of Prurigo Nodularis Treatments

COVID-19 Impact Analysis

The COVID-19 pandemic has led to disruptions in healthcare services worldwide. Non-urgent medical appointments and elective procedures, including dermatology consultations, have been postponed or canceled in many regions. This has affected the diagnosis and management of prurigo nodularis, potentially delaying patient treatment access.

The pandemic has resulted in changes in patient behavior, including reduced healthcare-seeking conduct due to concerns about potential exposure to the virus. Patients with prurigo nodularis may have postponed or avoided seeking medical attention or follow-up visits, leading to underdiagnosis and undertreatment.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict and its associated challenges may divert resources and attention from research and development activities related to prurigo nodularis. Funding and focus on medical research may shift towards more immediate priorities, impacting the progress of new treatment options or clinical trials for prurigo nodularis.

The conflict can have broader socioeconomic impacts, affecting individuals' and healthcare systems' financial stability and resources. Economic instability, loss of livelihoods, and displacement can result in limited financial resources for patients and healthcare providers, impacting the affordability and availability of prurigo nodularis treatments.

Segment Analysis

The Global Prurigo Nodularis Treatment Market is segmented based on product, distribution channel, and region.

Based on the Product, the Corticosteroids Segment is Expected to Dominate the Market Share

The corticosteroid market held 35.6% of the Global Prurigo Nodularis Treatment Market share in 2022. Corticosteroids have demonstrated effectiveness in managing the symptoms of prurigo nodularis, including reducing itching, inflammation, and the formation of nodules. They provide quick relief and are often prescribed as first-line treatments.

Corticosteroids are often combined with other treatments, such as emollients or topical immune modulators, to enhance the overall management of prurigo nodularis. Corticosteroids are generally more cost-effective than other treatment options, making them accessible to a wide range of patients. This affordability aspect also contributes to their market dominance.

For instance, in March 2023, statistically significant and clinically meaningful improvements were seen among adult patients who have prurigo nodularis (PN) following their treatment with dupilumab (Dupixent) over 24 weeks in the randomized, double-blind, placebo-controlled phase 3 LIBERTY PN-PRIME and LIBERTY PN-PRIME2 trials.

Geographical Analysis

North America Holds the Largest Market Share due to the Large Patient Population and Advanced Healthcare Infrastructure.

North America holds the 42.7% market share for the prurigo nodularis treatment market in 2022 due to the large patient population and advanced healthcare infrastructure. North America has a substantial patient population, including a high prevalence of prurigo nodularis cases. The large patient base creates a demand for effective treatments and contributes to the market's growth.

North America is known for its advanced healthcare infrastructure, including well-established medical facilities, specialized dermatology centers, and access to advanced diagnostic tools. This infrastructure supports accurate diagnosis and effective treatment of prurigo nodularis, driving the market's growth.

Competitive Landscape

The major global players include: Menlo Therapeutics Inc., Pfizer Inc, Sanofi S.A., Kiniksa Pharmaceuticals Ltd., Astellas Pharma Inc, Eli Lilly and Company, GlaxoSmithKline, Galderma S.A., Trevi Therapeutics Inc, and Regeneron Pharmaceuticals Inc.

Why Purchase the Report?

• To visualize the Global Prurigo Nodularis Treatment Market segmentation based on product, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous prurigo nodularis treatment market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Prurigo Nodularis Treatment Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Capsaicin Creams
    • 4.1.1.2. Increasing Prevalence of Prurigo nodularis
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment
    • 4.1.2.2. Limited Treatment Options
  • 4.1.3. Opportunity
    • 4.1.3.1. Advancements and Innovations in Treatment Options
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Corticosteroids*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Anti-Histamines
• 7.4. Emollients
• 7.5. Capsaicin Cream
• 7.6. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. The U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. The UK
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Menlo Therapeutics Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Pfizer Inc.
• 11.3. Sanofi S.A.
• 11.4. Kiniksa Pharmaceuticals Ltd.
• 11.5. Astellas Pharma Inc.
• 11.6. Eli Lilly and Company
• 11.7. GlaxoSmithKline
• 11.8. Galderma S.A.
• 11.9. Trevi Therapeutics Inc.
• 11.10. Regeneron Pharmaceuticals Inc.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us